Promentis receives grant to develop schizophrenia drugs
Milwaukee-based Promentis Pharmaceuticals Inc. has received a three-year, $1.8 million award from the National Institutes of Health to develop more effective drugs to treat schizophrenia. (JOURNAL SENTINEL, 9/27)
To access this content, you must purchase a Premium membership, or log in if you are a member.
